- 1 Elevated 11-oxygenated androgens are not a major contributor to HPG-axis disturbances
- 2 in adults with congenital adrenal hyperplasia due to 21-hydroxylase deficiency
- 3 Matthias K. Auer¹, Luisa Paizoni¹, Meike Neuner¹, Christian Lottspeich¹, Heinrich Schmidt², Martin
- 4 Bidlingmaier¹, James Hawley³, Brian Keevil³, Nicole Reisch¹
- ⁵ ¹Medizinische Klinik and Poliklinik IV, Klinikum der Universität München, LMU München, Munich,
- 6 Germany
- 7 ²Department of Pediatric Endocrinology, Dr. von Haunersches Children's Hospital, Klinikum der
- 8 Universität München, LMU München, Munich, Germany
- 9 ³Department of Clinical Biochemistry, Manchester University Foundation NHS Trust, Manchester
- 10 Academic Health Sciences Centre, Southmoor Rd, Manchester, UK
- 11

12 Corresponding author:

- 13 Nicole Reisch
- 14 Medizinische Klinik and Poliklinik IV, Klinikum der Universität München
- 15 Ziemssenstr. 1
- 16 80336 München
- 17 Germany
- 18 Email: Nicole.reisch@med.uni-muenchen.de

19

Declaration of interest

- All authors have declared that no conflict of interest exists
 All authors have declared that no conflict of interest exists
 All authors have declared that no conflict of interest exists
- 27
- 28

29 Highlights

э	n	
<u> </u>	U	
-	~	

- The 11-oxygenated androgens 11-ketotestosterone and 11β-hydroxyandrostenedione are
 significantly elevated in men with CAH with hypogonadotropic hypogonadism and women with
 amenorrhea.
- Elevated 17-OHP levels in male patients and elevated testosterone levels in female patients are
- 35 however the dominant predictor of HPG-axis disturbances.
- 36 11-oxygenated androgens are not predictive for testicular adrenal rest tumors in men with CAH
- 11-ketotestosterone and 11β-hydroxyandrostenedione levels do not seem to be influenced by
 intake of oral contraceptives.

- **F 2**

54 **Abstract**

- 55 Context
- 56 Hypothalamus-pituitary-gonadal (HPG)-axis disturbances are a common phenomenon in patients with
- 57 classic congenital adrenal hyperplasia (CAH). 11-oxygenated androgens have been suggested to play
- 58 a role in this context.
- 59 Design
- 60 Cross-sectional single center study including 89 patients (N=42 men, N=55 women) with classic CAH.

61 Main Outcome Measures

- 62 Independent predictors for hypogonadism in men and secondary amenorrhea in women with CAH with
- 63 a special focus on 11-ketotestosterone (11KT) and 11β-hydroxyandrostenedione (11OHA4).

64 Results

65 Hypogonadotropic hypogonadism was present in 23% of men and 61% of those women currently not 66 on contraceptives suffered from irregular menstrual cycles or amenorrhea. Testicular adrenal rest 67 tumor (TART) was documented in 28% of men. While 11KT (3.5x) and 11OHA4 (5.7x) among other 68 adrenal steroids were significantly elevated in men with hypogonadism, in stepwise logistic regression, 69 the only significant independent predictor for hypogonadism were elevated 17-OHP levels (B = 0.006; 70 p = 0.039). Although 11KT (5.2x) and 11OHA4 (3.7x) levels were also significantly higher in women 71 with amenorrhea in comparison to those with a regular cycle, the only significant predictor for 72 amenorrhea were elevated total testosterone levels (B = 1.806; p = 0.040). 11-oxygenated androgens 73 were not different in those with TART and those without. Of note, there were no significant differences 74 in 110HA4 or 11KT between those with a regular cycle and those currently on hormonal 75 contraceptives.

76 Conclusions

11-oxygenated androgens do not seem to add additional information for explaining menstrual
 disturbances and hypogonadism in patients with CAH in comparison to established marker of disease
 control.

80

81 Keywords

82 Congenital adrenal hyperplasia, hypogonadism, menstrual cycle, 11-ketotestosterone, 11-oxygenated

83 androgens

84

85 Abbreviations

86	11KT	11-ketotestosterone
87	110HA4	11β-hydroxyandrostenedione
88	17-OHP	17α-hydroxyprogesterone
89	ACTH	Adrenocorticotropic hormone
90	AR	Androgen receptor
91	САН	Congenital adrenal hyperplasia
92	СРА	Cyproterone acetate
93	DHEAS	Dehydroepiandrosterone sulfate
94	ER	Estrogen receptor
95	FC	Fludrocortisone
96	FSH	Follicle-stimulating hormone
97	GC	Glucocorticoid(s)
98	GnRH	Gonadotropin releasing hormone
99	нс	Hydrocortisone
100	HPG	Hypothalamus-pituitary-gonadal
101	LH	Luteinizing hormone
102	PR	Progesterone receptor
103	SERM	Selective estrogen receptor modulator
104	SHBG	Sex hormone binding globulin
105	SV	Simply virilizing
106	SW	Salt-wasting
107	TART	Testicular adrenal rest tumor

Acknowledgments

110 We thank all participants for taking part in this study

112 Funding

114 This work was supported by the IFCAH grant 2013 to NR and by the Deutsche

- 115 Forschungsgemeinschaft (Heisenberg Professorship 325768017 to NR and Projektnummer:
- 116 314061271-TRR205 to NR). The authors declare no competing interests.

- 12.

- ___

134 **1. Introduction**

135 Congenital adrenal hyperplasia (CAH) encompasses a group of hereditary autosomal recessive 136 disorders that are characterized by mutations in key enzymes of cortisol synthesis. Among these, 137 patients affected by mutations in the 21-alpha hydroxylase gene are the largest entity (1). Depending 138 on the severity of the underlying mutation, patients are either suffering from isolated glucocorticoid-139 (simply virilizing form= SV) or additional mineralocorticoid-deficiency, when less than 1-2% of 140 enzymatic activity is retained (salt-wasting = SW). Glucocorticoid deficiency in turn results in ACTH 141 overstimulation due to the loss of hypothalamo-pituitary negative feedback which subsequently drives 142 excessive adrenal androgen production (2).

143 Hypothalamus-pituitary-gonadal (HPG)-axis disturbances are a common phenomenon in CAH patients 144 of both sexes. In particular in women in the fertile age, menstrual disturbances occur in up to 30% (3-145 5). The most obvious mechanism for this finding is the inherent extra-gonadal androgen and 146 progesterone production in CAH. Correspondingly, menstrual cycle disturbances in female patients 147 with CAH have been associated with poor treatment control as indicated by increased 17-OHP, 148 testosterone, progesterone and androstenedione levels (6). In line, a recent study from the DSD-life 149 cohort demonstrated that an androstenedione/testosterone ratio ≥1, indicating excessive adrenal 150 testosterone production, is a strong predictor of sub-normal testosterone levels in men with CAH (7). 151 Most of these patients correspondingly present with low or inadequately low gonadotropin levels 152 indicating hypogonadotropic hypogonadism, while some patients also show signs of primary testicular 153 damage mainly due to testicular adrenal rest tumor (TART) formation (7-9)

However, HPG-axis disturbances can also be found in patients who are regarded well controlled based on the aforementioned treatment markers (4,10). The exact culprit for HPG disturbances is therefore not always clear, as all major steroids, namely testosterone, estradiol and progesterone are important parts of the HPG feedback loop (11).

In recent years, a further class of adrenal-derived androgens has come into focus in the context of CAH. These are 11-oxygenated 19-carbon androgens, in particular 11-ketotestosterone (11KT) and 11β-hydroxyandrostenedione (11OHA4). Androstenedione can be converted to 11OHA4 by 11βhydroxylase, then to 11-ketoandrostenedione through the action of 11β-hydroxysteroid dehydrogenase type 2 and finally to 11KT (12,13). It has been demonstrated that 11KT and its 163 derivate 11KT-dihydrotestosterone act at the androgen receptor with equal potency to the classic 164 testosterone and dihydrotestosterone (DHT) (14). Correspondingly, it has been shown that these 165 steroids are significantly elevated in patients with classic CAH (15). While it has been suggested that 166 elevated 11KT levels might contribute to HPG-suppression at the hypothalamic and pituitary level, 167 their clinical relevance has still to be determined (16). Although testosterone exerts direct negative 168 effects at the hypothalamic levels via AR binding (17,18), estradiol seems to be the dominant 169 suppressor in this context (19). As 11KT cannot be directly aromatized questions a dominant role in 170 HPG suppression in this context (14).

171 In the present study, we were therefore interested if 11-oxygenated androgens, in particular 11-KT 172 would add information on HPG-axis disturbances in adult patients with CAH due to 21-hydroxylase 173 deficiency in addition to established markers of disease control.

In detail, we hypothesized that 11KT would be higher in men with hypogonadotropic hypogonadism than in those with eugonadism, that 11OHA4 would be higher in males with TART than in those without and that 11KT and 11OHA4 would be higher in women with menstrual irregularities in contrast to those with eumenorrhoea. In an exploratory analysis we were further interested if 11KT and 11OHA4 would differ between women with a regular cycle and those on oral contraceptive therapy to estimate if these potential covariates should be accounted for in the clinical context if our main hypotheses would hold true.

181 2. Material and Methods

182 Subjects

We included 89 patients (N=42 men, N=55 women) of whom 58 were suffering from SW and 31 of the SV form of CAH. All patients were seen at the outpatient clinic of the Medizinische Klinik IV, Klinikum der Universität München, LMU Munich. All patients were directly approached during a regular visit in the outpatient clinic. The recruitment period was from January 2012 to January 2014. The local ethics committee of the Ludwig-Maximilians-Universität München approved the study protocol. All participants provided their written informed consent.

189

190 Testicular ultrasound

191 Testicular ultrasound was performed in the Department of Endocrinology in the University Hospital 192 Munich by a trained sonographer (Siemens Acuson S2000). Testicular ultrasound was performed 193 documenting testicular masses. Greyscale and color Doppler ultrasonography were obtained in the 194 longitudinal and transverse planes using a 15MHz transducer. Data on TART was missing in seven 195 men.

196

197 Hormone assays and hormonal control

Blood was drawn in fasting patients in the morning between 8 and 10 a.m., roughly 2 hours after the intake of the morning medication of participants. Concentrations of adrenocorticotrophic hormone (ACTH), sex hormone binding globulin (SHBG) and DHEAS were determined using the Liaison chemiluminescence immunoassays (DiaSorin, Sallugia, Italy).

Total testosterone, 17-OHP, androstenedione, 11-KT and 11OHA4 were quantified by LC-MS/MS.
Steroid extraction and quantitation was carried out as previously described (20).

204 Daily doses of glucocorticoids and mineralocorticoids were evaluated. Equal hydrocortisone doses 205 were calculated according to their suggested androgen-suppressive capacity (hydrocortisone=1, 206 prednisolone=4, dexamethasone=70) and adjusted to the patients' body surface area (2). In men, 207 hypogonadism was defined as having a low testosterone level <12nmol/l (21)(39). Hypogonadotropic 208 hypogonadism was defined as having low testosterone levels with inappropriately normal or low 209 LH/FSH. Secondary amenorrhea was defined as not having had a spontaneous menstrual bleeding 210 during the last six months prior to study inclusion, while irregular cycles were defined as having as 211 cycle length that was less than 21 or more than 35 days (22).

212

213 Statistical analysis

214 Statistical analysis was performed using PASW Statistics (formerly SPSS) Version 22.0 for Windows.

Sample characteristics were compared using χ2 tests for categorical variables and the Mann-Whitney
 U test for continuous variables.

217 Spearman correlation was performed for univariate correlations. Partial regression analyses with LH 218 and FSH as a dependent variable and potential influential factors as independent variables were 219 performed adjusted for age and BMI. Separate multivariate regression analyses were used to identify 220 independent contributors for hypogonadism in men and secondary amenorrhea in women. Due to the 221 strong correlation among most steroid measures, variables were mean centered before addition to the

222	model. A two-block linear regression analysis was carried out to assess the contribution of different
223	variables. Block 1 included age and BMI using a forced entry method. In Block 2, we added CAH-
224	specific covariates using forward stepwise regression analysis. A two-sided P value of <0.05 was
225	considered statistically significant.

226

227 **3. Results**

228

229 General characteristics

The median age of the cohort was 28 years (range 18-61). The median GC equivalence dosage was 16.0 mg/m2/d for men and 14.6 mg/m2/d for women. According to the expected (residual) enzymatic activity, thirteen (21.0% of whom data was available) patients were assigned to genotype group 0, 21 (33.9%) to genotype group A, 24 (38.7%) to genotype group B and four (6.5%) patients to genotype group C (23).

235 Of those investigated, TART was present in eleven patients (28.2%). 23% presented with 236 hypogonadotropic hypogonadism. There were no men with primary hypogonadism.

Thirty seven percent of women were currently receiving hormonal contraceptive therapy. From those without oral contraception and in premenopausal age, 38.7% had a regular cycle while 25.8% had irregular menses and 35.5% were amenorrhoeic. Three women were postmenopausal (6%). At study inclusion, of those with a regular cycle, 75% were in the follicular and 25% in the luteal phase of the cycle (Table 1).

242 Table 1 General characteristics

		Men		Women		
		N (39)	%	N (50)	%	р
Mutation						
Mutation group	0	8	21	5	10	0.293
	A	12	31	9	18	
	В	8	21	16	32	
	С	2	5	2	4	
	Unknown	9	23	18	36	
Simply virilizing		12	31	19	38	
Salt wasting		27	69	32	64	0.477

TART	Yes	11	28.2	NA	NA		
	unilateral	3		NA	NA		
	bilateral	7		NA	NA		
	No	21	53.8	NA	NA		
	Missing	7	17.9	NA	NA		
Hypogonadism			0				NA
	Eugonadism	30	77	NA	NA		
	Sec. hypogonadismus	9	23	NA	NA		
	Primary hypogonadism	0	0	NA	NA		
Cycle	Oral contraception	NA	NA	16	32		NA
	Regular cycle	NA	NA	12	24	38.7*	
	Follicular	NA	NA	9	12	75%**	
	Luteal	NA	NA	3	8	25%**	
	Irregular menses	NA	NA	8	16	25.8*	
	Secondary amenorrhea	NA	NA	11	22	35.5*	
	Postmenopausal	NA	NA	3	6		
			0		0		
GC	None	0	0	2	4		0.359
	HC	18	46	19	38		
	Predniso-ne/-lone	16	41	24	48		
	Dexa	4	10	3	6		
	HC + Dexa	0	0	3	6		
	Predniso-ne/-lone +Dexa	1	3	0	0		
		Median		Median			
HC Equivalence- dosage (mg/m²)		14.6		16.0			0.143

243 Man-Whitney U, X2 test

244 *Of those not on contraception

245 **of those with regular cycle

246 NA not applicable

247 TART: testicular adrenal rest tumor

248 HC: hydrocortisone

249 GC: glucocorticoid

- 250 Dexa: Dexamethasone
- 251 TART: Testicular adrenal rest tumor

252

253 There were no significant differences in androstenedione,17-OHP,11KT and 11OHA4 levels between

254 men and women. (Table 2).

256

257 Table 2 Anthropometric measures and hormone values

	Men			Women			
	Median	Percei	ntiles	Median Perc		entiles	р
		25	75		25	75	
Age	28.0	24.0	40.0	29.0	24.0	38.0	0.990
BMI (kg/m²)	26.0	22.7	29.9	26.8	22.3	30.8	ND
Waist (cm)	95.0	81.3	100.8	78.0	70.0	92.0	ND
Body fat (%)	25.6	13.1	25.7	34.3	18.5	33.2	ND
Lean mass (%)	57.1	52.5	63.1	44.4	40.1	48.8	ND
LH (U/I)	3.0	1.8	4.7	3.4	0.9	5.7	ND
FSH (U/I)	5.0	2.8	7.2	4.6	2.8	6.9	ND
ACTH (pg/ml)	11.0	6.0	55.0	10.0	4.0	29.0	0.219
Testosterone (nmol/l)	13.0	10.9	16.7	0.5	0.2	1.5	ND
Androstenedione (nmol/l)	3.6	1.1	8.2	2.0	0.9	6.0	0.155
17-OHP (nmol/l)	23.3	5.2	153.6	14.0	2.8	64.5	0.125
11KT (nmol/l)	1.2	0.3	2.4	0.6	0.2	2.4	0.335
110HA4 (nmol/l)	2.0	0.3	8.0	1.3	0.3	5.5	0.550
DHEAS (µg/ml)	0.3	0.2	0.5	0.0	0.0	0.2	ND
SHBG (nmol/l)	33.5	24.1	39.1	57.8	39.2	145.1	ND
A/T-ratio	0.30	0.1	0.7	3.7	3.5	4.8	ND
11KT/T-ratio	0.1	0.02	0.24	1.2	1.0	1.7	ND
FAI (%)	12.4	9.0	17.2	0.2	0.1	0.8	ND
HOMA-IR	1.6	1.1	2.0	2.2	1.0	3.4	0.190

258 Mann-Whitney U

259 ND not determined

260 FAI: free androgen index

261 110HA4: 11-β hydroxyandrostenedione

262 11KT: 11-ketotestosterone

263 T: Testosterone

264 265

205

266 Correlations between steroid measures

267	In men, there was a strong positive correlation between 11KT with ACTH (0.845; p < 0.001),
268	androstenedione (R = 0.933; p < 0.001), 17-OHP (R = 0.942; p < 0.001) and the
269	androstenedione/testosterone (A/T)-ratio (R = 0.837; p < 0.001). A negative correlation of 11KT with
270	testosterone was only seen on a trend level (R = -0.278 ; p = 0.087) and there was no significant

271 correlation with the free androgen index (FAI). 110HA4 correlated positively with ACTH (R = 0.868; p

272 < 0.001), androstenedione (0.944; p < 0.001), 17-OHP (R = 0.947; p < 0.001) and the A/T-ratio (R =

273 0.857; p < 0.001). 11KT and 110HA4 also were strongly correlated (R = 0.976; p< 0.001).

In women, there was a positive correlation of 11KT with ACTH (R = 0.552; p < 0.001), total testosterone (R = 0.899; p < 0.001), androstenedione (R = 0.889; p< 0.001), 17-OHP (R = 0.915; p < 0.001), DHEAS (R = 0.618; p < 0.001) and the FAI (R = 0.780; p < 0.001). 11OHA4 correlated positively with ACTH (R = 0.604; p < 0.001), total testosterone (R = 0.875; p < 0.001), androstenedione (R = 0.886; p< 0.001), 17-OHP (R = 0.915; p < 0.001), DHEAS (R = 0.637; p < 0.001) and the FAI (R = 0.781; p < 0.001). The correlation between 11KT and 11OHA4 was weaker than in men (R = 0.477; p< 0.001).

281 Presence of TART

There were no significant differences in steroid measures between those with and without TART. There was also no difference in ACTH or gonadotropin levels, HC equivalence dosage or SV vs. SW (data not shown).

285 Hypogonadism in men

Androstenedione levels were significantly higher in men with secondary hypogonadism than in those with eugonadism (4.5x; p = 0.023). A similar pattern could be observed with 17-OHP (14.4x; p = 0.007), 11KT (3.5x; p = 0.020), 11OHA4 (5.7x, p = 0.009) and ACTH (9.3x; p = 0.004) (Figure 1).

289

290

291

292

293

294

295

297

298



299 Figure 1 Differences between men with hypogonadism and eugonadism

300

Fig 1 Androstenedione levels were significantly higher in men with secondary hypogonadism than in those with eugonadism (4.5x; p = 0.023). Same was true for 17-OHP (14.4x; p = 0.007), 11KT (3.5x; p = 0.020), 11OHA4 (5.7x, p = 0.009) and ACTH (9.3x; p = 0.004). (Boxes represent the first to the third quartile, vertical line indicates medians, crosses indicate outliers).

305

306 LH/FSH in men

307 In men, according to partial correlation analysis, adjusted for BMI and age, there was no significant 308 correlation of LH with any steroid measure. There was also no correlation with HC equivalence 309 dosage, type of GC (HC = 0 vs. synthetic GC = 1) or with regard to SV vs. SW.

310 In contrast, there were comparably strong negative correlations of androstenedione (R = -0.330; p =

311 0.048), 17-OHP (R = -0.329; p = 0.047); 11KT (R = -0.368; p = 0.025), 11OHA4 (R = - 0.361; p = 0.047); 0.048), 0.

312 0.028), the A/T-ratio (R = -0.387; p = 0.018) as well as the KT/T-ratio (R = -0.383; p = 0.019) with FSH.

- 313 There was no significant correlation with LH or FSH when adding KT+T as a new variable, given then
- 314 idea that both androgens should have equimolar androgenic potency according to the literature.

315 Predictors of hypogonadism in men

- 316 The only significant predictor for hypogonadism in men were elevated 17-OHP levels (B = 0.006; p =
- 317 0.039) in a stepwise logistic regression (0 = Eugonadism, 1= hypogonadism), including age, BMI,
- ACTH, androstenedione, 17-OHP, DHEAS, 11KT and 11OHA4. As expected, finding also remained
- significant when adding HC-equivalence dosage as well as HC (0) vs GC (1) to the model (Table 3).

320 Table 3 Stepwise regression of potential predictors of hypogonadism in men

Variable	В	S.E.	р	Exp(B)	95% C.I.	95% C.I.
					Lower	Upper
Age*	037	.048	.435	.963	0.877	1.058
BMI*	004	.105	.966	.996	0.811	1.222
17-OHP	.006	.003	.039	1.006	1.000	1.011

321 *Forced entryincluding ACTH, androstenedione, 17-OHP, DHEAS, 11KT and 110HA4 as independent

322 variables.

323 All variables were mean-centered. C.I. confidence interval

324

325 Amenorrhea in women

326 ACTH (4.3x; p = 0.003), androstenedione (2.5x; p = 0.019), 17-OHP (8.1x; p = 0.002), 11KT (5.2x; p =

327 0.002), 110HA4 (3.7x; p = 0.023) and testosterone (3.1x; p = 0.007) were significantly higher in

328 women with amenorrhea versus regular cycling women (Figure 2).

329

- 330
- 331
- 332

333

- 334
- 335
- 336

337

- 339
- 340
- 540
- 341

342 Figure 2 Differences between regular cycling and amenorrhoeic women



343

344

Fig 2 ACTH (4.3x; p = 0.003), androstenedione (2.5x; p = 0.019), 17-OHP (8.1x; p = 0.002), 11KT (5.2x; p = 0.002), 11OHA4 (3.7x; p = 0.023) and testosterone (3.1x; p = 0.007) were significantly higher in women with amenorrhea in comparison to those with a regular cycle. (Boxes represent the first to the third quartile, vertical line indicates medians, crosses indicate outliers).

349

Equivalence dosage of HC was lower (12.7mg/m² vs 16.4mg/m²; p = 0.019). There was no difference in terms of GC vs HC use or HOMA-IR. There was also no difference in DHEAS levels and the A/Tratio. There was no significant difference in these parameters between those with irregular and those with a regular cycle (data not shown).

354 Oral contraceptive use

Androstenedione (p = 0.011), the FAI (p = 0.001) and DHEAS (p = 0.049) were significantly lower in women with a regular menstrual cycle in comparison to women currently taking an oral contraceptive pill, while there was no difference in total testosterone, 17-OHP, 11KT or 11OHA4 (Figure 3).



359

360 Figure 3 Oral contraception vs regular cycle

361



362

Fig 3 When comparing those with a regular menstrual cycle with those currently taking an oral contraceptive pill, androstenedione (p = 0.011), the FAI (p = 0.001) and DHEAS (p = 0.049) were significantly lower, while there was no difference in total testosterone, 17-OHP, 11KT or 11OHA4.). (Boxes represent the first to the third quartile, vertical line indicates medians, crosses indicate outliers).

368

369 Predictors of amenorrhea

370 Only higher testosterone levels were significantly associated with amenorrhea (B = 1.806; p = 0.040)

in a logistic regression analysis including age, BMI (Enter) (0 = amenorrhea, 1= regular cycle), ACTH,

372 androstenedione, 17-OHP, DHEAS, total testosterone, free testosterone, the A/T-ratio, 11KT,

373 110HA4, and the T/KT-ratio (stepwise) (Table 4).

374

376

377

Variable	В	S.E.	р	Exp(B)	95% C.I.	95% C.I.
					Lower	Upper
Age*	-0.097	0.111	0.381	.908	0.731	1.127
BMI*	-0.024	0.095	0.804	.977	0.812	1.176
Testosterone	1.806	0.877	0.040	6.085	1.091	33.955
Constant	0.796	0.803	0.321	2.216		

378 Table 4 Stepwise regression of potential predictors of amenorrhea

379 *Forced entry; Stepwise including ACTH, androstenedione, 17-OHP, DHEAS, total testosterone, free

testosterone, the A/T-ratio, 11KT, 110HA4, and the T/KT-ratio as independent variables. All variables
 were mean-centered. C.I. confidence interval.

382

4. Discussion

We could demonstrate in this relatively large cohort that 11-oxygenated androgens are significantly elevated in patients of both sexes with HPG-axis disturbances. They however do not seem to be the most relevant androgens in this context.

387 The prevalence of hypogonadism in men and menstrual irregularities in women in our cohort was 388 comparable to that reported in the literature (7,24) and hence emphasizes that HPG-axis disturbances 389 are still a fairly common issue in this patient population. Despite a significant elevation of 11KT and 390 11OHA4, being in accordance with earlier studies (16), 17-OHP was a better predictor of 391 hypogonadism in male patients. Our data therefore do not indicate a leading role of 11KT in HPG-axis 392 suppression. This may be due to the fact that 11KT cannot be converted into estrogenic steroids and 393 many effects that had originally been attributed to testosterone in men are actually mediated via 394 aromatization to estradiol (25). This also includes sex steroid regulation at the hypothalamus/pituitary 395 level (19).

The significant role of 17OHP may be explained by the fact that progesterone is also a very potent suppressor of the HPG-axis in men (26,27). As 17-OHP is a direct metabolite of progesterone, it is a

potent agonist of the PR (28) as also indicated by a strong positive correlation between both steroidsin patients with CAH (29).

400 In contrast to previous work (16) and our initial hypothesis, neither 11KT nor 110HA4 were elevated in 401 men with TART and most steroid measures, including 11KT and 11OHA4 showed a negative instead 402 of a positive correlation with FSH as a potential marker of gonadal damage. Although our cohort was 403 age-wise comparable to those adult patients reported by Turcu et al., a considerable proportion of their 404 patients with TART were children. While TARTs in younger patients might still respond to HPA-axis 405 suppression, they seem to become less modifiable in the long-term due to fibrotic modifications (30). 406 In line, presence of TART has been associated with poor treatment quality in some (8) but not all 407 studies (9,31). Despite the factor of age, we cannot exclude that there were further differences in non-408 recorded potential confounders such as long-term disease control distinguishing our patient groups.

11KT and 11OHA4 levels were also higher in women with secondary amenorrhea than in those with a regular cycle, as having been reported before (16). But again, when adding other markers of disease control to our model, testosterone was superior in explaining amenorrhea. Correspondingly, menstrual cycle disturbances in female patients with CAH have been associated with poor androgen control (6). Testosterone modulates GnRH-pulse frequency and therefore interferes with the complex hormonal interplay during the menstrual cycle (32). In addition, it also has direct effects on the endometrium (33).

Of note, there were no significant differences in 11KT or 11OHA4 between those with a regular cycle and those currently taking hormonal contraceptives. This may be due to a lower binding affinity for SHBG that has been suggested but not yet demonstrated for these steroids. This could be of clinical relevance, as this might explain why some patients benefit less from oral contraceptive treatment with regard to hyperandrogenic symptoms such as hirsutism and acne (34). However, prospective studies are needed to substantiate this finding.

There are several limitations of our study. Firstly, due to the cross-sectional design we can only show associations and no causality between dependent and independent variables. Prospective studies with modifying interventions are therefore needed. A further limitation in this context is that, in contrast to the general recommendation, the definition on hypogonadism in our study was based on a single, instead of two testosterone measures in the morning (21). However, diurnal variance of testosterone

427 and LH in CAH do generally differ from the general male population due to the extra-gonadal 428 androgen production and also depend on GC pharmacokinetics (1). A further limitation of our study is 429 that we only used a single steroid measurement in the morning for our analyses. Steroid 430 measurements from blood drawn before the intake of the morning GC dosage might therefore yield 431 other results. However, all patients included were either receiving a morning dosage of HC or 432 prednisolone or an evening dosage of dexamethasone which show, given the wide inter-individual 433 variability, a comparable suppression profile for the chosen time window (35,36).

Lastly, although we in investigated a large group of adult patients with classic CAH, given the rarity of
the disease, subgroups were rather small, stepwise regression had to be used for our final models.
Nonetheless, given the strong differences in steroid markers between groups we consider our results
to be valid.

438 **5.** Conclusion

439 In the present study, 11KT and 11OHA4 did not seem to add additional information to the 440 understanding of HPG-axis disturbances in CAH. Further studies have to show if 110xC19 steroids are 441 of relevance for explaining for other health issues in CAH. It might be of particular interest, if they 442 could be a superior biomarker of disease control. To our knowledge it has not yet been shown to what 443 extent 11-oxygenated androgens show a diurnal variation, potentially addressing the still problematic 444 issue of timing of blood sampling with regard to different GC treatment regimens. Former approaches 445 to overcome these restrictions like serial salivary (36) or blood sampling (37), or hair steroid measures 446 (52) are on the one hand very time consuming and on the other hand have so far not yet been proven 447 to be superior in terms of predicting clinically relevant long-term outcomes. Lastly, it would have to be 448 demonstrated that 11KT can be independently targeted by treatment-modification, independent of 449 other adrenal androgens.

450

451

452

454			
455			
456			
457			
458	6. References		

- 459
- Speiser PW, Arlt W, Auchus RJ, Baskin LS, Conway GS, Merke DP, Meyer-Bahlburg HFL,
 Miller WL, Murad MH, Oberfield SE, White PC. Congenital Adrenal Hyperplasia Due to Steroid
 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. J Clin
 Endocrinol Metab. 2018;103(11):4043-4088.
- White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
 Endocrine reviews. 2000;21(3):245-291.
- 4663.Turcu AF, Mallappa A, Elman MS, Avila NA, Marko J, Rao H, Tsodikov A, Auchus RJ, Merke467DP. 11-Oxygenated Androgens Are Biomarkers of Adrenal Volume and Testicular Adrenal468Rest Tumors in 21-Hydroxylase Deficiency. The Journal of clinical endocrinology and469metabolism. 2017;102(8):2701-2710.
- 470
 47. Stikkelbroeck NM, Sweep CF, Braat DD, Hermus AR, Otten BJ. Monitoring of menstrual cycles, ovulation, and adrenal suppression by saliva sampling in female patients with 21-hydroxylase deficiency. Fertility and sterility. 2003;80(4):1030-1036.
- 473 5. RICHARDS GE, GRUMBACH MM, KAPLAN SL, CONTE FA. The Effect of Long Acting
 474 Glucocorticoids on Menstrual Abnormalities in Patients with Virilizing Congenital Adrenal
 475 Hyperplasia*. The Journal of Clinical Endocrinology & Metabolism. 1978;47(6):1208-1215.
- Bachelot A, Chakhtoura Z, Plu-Bureau G, Coudert M, Coussieu C, Badachi Y, Dulon J, Charbit B, Touraine P, Group CS. Influence of hormonal control on LH pulsatility and secretion in women with classical congenital adrenal hyperplasia. European journal of endocrinology. 2012;167(4):499.
- 480 7. Engels M, Gehrmann K, Falhammar H, Webb EA, Nordenstrom A, Sweep F, Span PN, van
 481 Herwaarden AE, Rohayem J, Richter-Unruh A. Gonadal function in adult male patients with
 482 congenital adrenal hyperplasia. European journal of endocrinology. 2018;EJE-17-0862.
- 483 8. King TF, Lee MC, Williamson EE, Conway GS. Experience in optimizing fertility outcomes in men with congenital adrenal hyperplasia due to 21 hydroxylase deficiency. Clinical endocrinology. 2016;84(6):830-836.
- Reisch N, Flade L, Scherr M, Rottenkolber M, Pedrosa Gil F, Bidlingmaier M, Wolff H,
 Schwarz H-P, Quinkler M, Beuschlein F. High prevalence of reduced fecundity in men with
 congenital adrenal hyperplasia. The Journal of Clinical Endocrinology & Metabolism.
 2009;94(5):1665-1670.
- 490 10. Richards G, Grumbach M, Kaplan S, Conte F. The effect of long acting glucocorticoids on 491 menstrual abnormalities in patients with virilizing congenital adrenal hyperplasia. The Journal 492 of Clinical Endocrinology & Metabolism. 1978;47(6):1208-1215.
- 493 11. Kaprara A, Huhtaniemi IT. The hypothalamus-pituitary-gonad axis: tales of mice and men.
 494 Metabolism. 2018;86(3-17.
- 495 12. Turcu AF, Rege J, Auchus RJ, Rainey WE. 11-Oxygenated androgens in health and disease.
 496 Nature Reviews Endocrinology. 2020;1-13.
- 497 **13.** Turcu AF, Auchus RJ. Clinical significance of 11-oxygenated androgens. Current opinion in endocrinology, diabetes, and obesity. 2017;24(3):252.
- Imamichi Y, Yuhki K-i, Orisaka M, Kitano T, Mukai K, Ushikubi F, Taniguchi T, Umezawa A, Miyamoto K, Yazawa T. 11-ketotestosterone is a major androgen produced in human gonads.
 The Journal of Clinical Endocrinology & Metabolism. 2016;101(10):3582-3591.
- Turcu AF, Nanba AT, Chomic R, Upadhyay SK, Giordano TJ, Shields JJ, Merke DP, Rainey
 WE, Auchus RJ. Adrenal-derived 11-oxygenated 19-carbon steroids are the dominant

504 androgens in classic 21-hydroxylase deficiency. European journal of endocrinology. 505 2016;174(5):601-609. 506 16. Turcu AF, Mallappa A, Elman MS, Avila NA, Marko J, Rao H, Tsodikov A, Auchus RJ, Merke 507 DP. 11-Oxygenated androgens are biomarkers of adrenal volume and testicular adrenal rest 508 tumors in 21-hydroxylase deficiency. The Journal of Clinical Endocrinology & Metabolism. 509 2017;102(8):2701-2710. 17. 510 Resko JA, Ellinwood WE. Negative feedback regulation of gonadotropin secretion by 511 androgens in fetal rhesus macaques. Biology of reproduction. 1985;33(2):346-352. 512 18. KEENAN BS, EBERLE AJ, SPARROW JT, GREGER NG, PANKO WB. Dihydrotestosterone 513 heptanoate: synthesis, pharmacokinetics, and effects on hypothalamic-pituitary-testicular 514 function. The Journal of Clinical Endocrinology & Metabolism. 1987;64(3):557-562. 515 19. Raven G, de Jong FH, Kaufman J-M, de Ronde W. In men, peripheral estradiol levels directly 516 reflect the action of estrogens at the hypothalamo-pituitary level to inhibit gonadotropin secretion. The Journal of Clinical Endocrinology & Metabolism. 2006;91(9):3324-3328. 517 518 20. Hawley JM, Adaway JE, Owen LJ, Keevil BG. Development of a total serum testosterone, 519 11β-hydroxyandrostenedione androstenedione. 17-hydroxyprogesterone, and 11-520 ketotestosterone LC-MS/MS assay and its application to evaluate pre-analytical sample 521 stability, Clinical Chemistry and Laboratory Medicine (CCLM), 2020;58(5);741-752. 522 21. Arver S, Lehtihet M. Current guidelines for the diagnosis of testosterone deficiency. Advances 523 in the management of testosterone deficiency. Vol 37: Karger Publishers; 2009:5-20. 524 22. Master-Hunter T, Heiman DL. Amenorrhea: evaluation and treatment. American family physician. 2006;73(8):1374-1382. 525 526 23. Krone N, Braun A, Roscher AA, Knorr D, Schwarz HP. Predicting phenotype in steroid 21-527 hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients 528 from southern Germany. The Journal of Clinical Endocrinology & Metabolism. 529 2000;85(3):1059-1065. Reichman DE, White PC, New MI, Rosenwaks Z. Fertility in patients with congenital adrenal 530 24. 531 hyperplasia. Fertility and sterility. 2014;101(2):301-309. 532 25. Finkelstein JS, Lee H, Burnett-Bowie S-AM, Pallais JC, Yu EW, Borges LF, Jones BF, Barry 533 CV, Wulczyn KE, Thomas BJ. Gonadal steroids and body composition, strength, and sexual 534 function in men. New England Journal of Medicine. 2013;369(11):1011-1022. 535 26. Auer MK, Fuss J, Stalla GK, Athanasoulia AP. Twenty years of endocrinologic treatment in transsexualism: analyzing the role of chromosomal analysis and hormonal profiling in the 536 537 diagnostic work-up. Fertility and sterility. 2013;100(4):1103-1110. 538 27. Fuss J, Claro L, Ising M, Biedermann SV, Wiedemann K, Stalla GK, Briken P, Auer MK. Does 539 sex hormone treatment reverse the sex-dependent stress regulation? A longitudinal study on 540 hypothalamus-pituitary-adrenal (HPA) axis activity in transgender individuals. 541 Psychoneuroendocrinology. 2019;104(228-237. 542 28. Attardi BJ, Zeleznik A, Simhan H, Chiao JP, Mattison DR, Caritis SN, Network OFPRU. 543 Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene 544 expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins. 545 American journal of obstetrics and gynecology. 2007;197(6):599. e591-599. e597. 546 29. HUGHES IA, WINTER JS. The relationships between serum concentrations of 17OH-547 progesterone and other serum and urinary steroids in patients with congenital adrenal 548 hyperplasia. The Journal of Clinical Endocrinology & Metabolism. 1978;46(1):98-104. 549 30. Claahsen-Van der Grinten H, Otten B, Stikkelbroeck M, Sweep F, Hermus A. Testicular 550 adrenal rest tumours in congenital adrenal hyperplasia. Best practice & research Clinical 551 endocrinology & metabolism. 2009;23(2):209-220. 552 31. Reisch N, Scherr M, Flade L, Bidlingmaier M, Schwarz H-P, Muller-Lisse U, Reincke M, 553 Quinkler M. Beuschlein F. Total adrenal volume but not testicular adrenal rest tumor volume is 554 associated with hormonal control in patients with 21-hydroxylase deficiency. The Journal of 555 Clinical Endocrinology & Metabolism. 2010;95(5):2065-2072. 556 32. Melrose P, Gross L. Steroid effects on the secretory modalities of gonadotropin-releasing 557 hormone release. Endocrinology. 1987;121(1):190-199. 558 33. Rose GL, Dowsett M, Mudge JE, White JO, Jeffcoate SL. The inhibitory effects of danazol, 559 danazol metabolites, gestrinone, and testosterone on the growth of human endometrial cells in 560 vitro. Fertility and sterility. 1988;49(2):224-228. 561 34. Martin KA, Chang RJ, Ehrmann DA, Ibanez L, Lobo RA, Rosenfield RL, Shapiro J, Montori 562 VM, Swiglo BA. Evaluation and treatment of hirsutism in premenopausal women: an endocrine 563 society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2008;93(4):1105-1120. 564

- S65
 S56
 S65
 Charmandari E, Matthews DR, Johnston A, Brook CG, Hindmarsh PC. Serum cortisol and 17hydroxyprogesterone interrelation in classic 21-hydroxylase deficiency: is current replacement therapy satisfactory? The Journal of Clinical Endocrinology & Metabolism. 2001;86(10):4679-4685.
- Gro schl M, Rauh M, Do rr HG. Cortisol and 17-hydroxyprogesterone kinetics in saliva after
 oral administration of hydrocortisone in children and young adolescents with congenital
 adrenal hyperplasia due to 21-hydroxylase deficiency. The Journal of Clinical Endocrinology &
 Metabolism. 2002;87(3):1200-1204.
- 573 **37.** Young M, Walker R, Riad-Fahmy D, Hughes I. Androstenedione rhythms in saliva in congenital adrenal hyperplasia. Archives of disease in childhood. 1988;63(6):624-628.